Shailen Jalali, MD
Interventional Pain Medicine · Havertown, PANPI 1427021351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,872 and has fallen 56.7% since, to $811 in 2025.
Across 165 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$997
- Nevro Corp.$676
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$373
- Foundation Fusion Solutions, LLC$298
- Curonix LLC$279
- Si-bone, Inc.$243
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$431%
- Food & beverage$5,07899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 37 | $997 |
| Nevro Corp. | 14 | $676 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $373 |
| Foundation Fusion Solutions, LLC | 3 | $298 |
| Curonix LLC | 2 | $279 |
| Si-bone, Inc. | 4 | $243 |
| Medtronic(2 entities) | 6 | $224 |
| SPR Therapeutics, Inc | 2 | $191 |
| MML US, Inc. | 2 | $157 |
| Vertos Medical, Inc. | 1 | $148 |
| Saluda Medical Americas, Inc. | 1 | $136 |
| International Rehabilitative Sciences, Inc | 1 | $131 |
| Spinal Simplicity, LLC | 1 | $121 |
| Tersera Therapeutics LLC | 11 | $121 |
| Collegium Pharmaceutical, Inc. | 5 | $112 |
| Boston Scientific | 4 | $94 |
| Pacira Therapeutics, Inc. | 4 | $85 |
| Relievant Medsystems, Inc. | 1 | $85 |
| Arbor Pharmaceuticals, Inc. | 6 | $83 |
| Biodelivery Sciences International, Inc. | 5 | $79 |
| Scilex Pharmaceuticals Inc. | 4 | $77 |
| Stimwave Technologies Incorporated | 3 | $67 |
| Biotronik NRO, Inc. | 3 | $57 |
| Globus Medical | 2 | $47 |
| Daiichi Sankyo Inc. | 3 | $45 |
| MDD US Operations, LLC | 3 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Forte Bio-pharma LLC | 1 | $26 |
| West Therapeutics Development, LLC | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Kaleo, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,122 in reported general payments places this provider in the 65th percentile of 59 interventional pain medicine providers in Pennsylvania.
See all interventional pain medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 29 | $28,101 |
| OxycontinOxycodone Hcl | 40 | $13,861 |
| Xtampza ErOxycodone Myristate | 19 | $9,893 |
| MovantikNaloxegol Oxalate | 19 | $7,445 |
| Oxycodone Hcl | 369 | $7,284 |
| Gabapentin | 330 | $6,694 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 237 | $5,442 |
| Tizanidine Hcl | 358 | $5,195 |
| Lidocaine | 43 | $5,169 |
| Buprenorphine | 20 | $4,716 |
| Pregabalin | 115 | $2,950 |
| Morphine Sulfate ErMorphine Sulfate | 137 | $2,946 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 111 | $2,624 |
| Oxcarbazepine | 43 | $2,135 |
| Baclofen | 96 | $1,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $112 | $37,99548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 interventional pain medicine providers in Pennsylvania.
Other interventional pain medicine in Havertown
- William IsaacsonHavertown$17
- Michael FishmanLebanon$670K
- David ProvenzanoSewickley$198K
- Michael FarrellPittsburgh$23K
- Farshad RashidianWest Chester$19K
- Chad MetzgerDarby$14K
- Jorge Rivero-BecerraPittsburgh$12K
- James BresnahanSpringfield$12K
- Jonathan SchollIndiana$11K
- Nathan MaltezosWest Chester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.